vimarsana.com

Latest Breaking News On - மையம் க்கு அளவு மருந்து - Page 1 : vimarsana.com

New study launched to more accurately diagnose early hepatocellular carcinoma

New study launched to more accurately diagnose early hepatocellular carcinoma A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual s likelihood of developing the cancer. HCC is the sixth most common cancer in the world but the third most common cause of cancer deaths globally. In Singapore, HCC is the third and fourth most common cause of cancer deaths, amongst males and females respectively. While potentially curative treatment is possible with early diagnosis, only 20% of HCC cases are detected at a stage where cure is possible. This investigator-initiated multi-centre study led by the National Cancer Centre of Singapore (NCCS) called EarLy DEtection of HCC: miRNA, microbiome and imaGing biomArkers in the evolution of chroNiC livEr Disease in a high-risk prospective cohort (ELEGANCE), addresses thi

Landmark study launched to detect liver cancer early in Singapore

 E-Mail IMAGE: Quantitative MR images of the liver from six patients presenting with liver cancer produced by Perspectum s LiverMultiScan which will be used in a new study led by National Cancer Centre. view more  Credit: Image credit: Mole DJ et al. Plos One. 2020;15(12):e0238568 Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need. Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual s risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.

Landscape study launched to detect liver cancer early in Singapore

 E-Mail IMAGE: Quantitative MR images of the liver from six patients presenting with liver cancer produced by Perspectum s LiverMultiScan which will be used in a new study led by National Cancer Centre. view more  Credit: Mole DJ et al. Plos One. 2020;15(12):e0238568 Singapore, 3 May 2021 - A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual s likelihood of developing the cancer. HCC is the sixth most common cancer in the world but the third most common cause of cancer deaths globally.[1] In Singapore, HCC is the third and fourth most common cause of cancer deaths, amongst males and females respectively.[2] While potentially curative treatment is possible with early diagnosis, only 20% of HCC cases are detected at a stage where cure is possible. This investigator-initiated multi-centre s

COVID is down in Connecticut, but it s unclear why

COVID is down sharply in CT. No one knows exactly why. FacebookTwitterEmail 1of5 Maryanne Lenhardt gets a COVID-19 vaccination, Wednesday, Feb. 10, 2021, at Central High School in Bridgeport, Conn. The mass vaccination clinic is one of several ways Bridgeport officials are trying to fight the low vaccination rates many cities across the country are seeing compared with wealthier suburbs. (AP Photo/Mark Lennihan)Mark Lennihan / Associated PressShow MoreShow Less 2of5 Fifty individuals 75 and older received their COVID-19 vaccine Tuesday morning at Cross Street AME Zion Church in Middletown, as part of the city s effort to inoculate older members of the congregation. The Black community has a longstanding distrust of the medical system, according to the Rev. Robyn Anderson, director of the Ministerial Health Fellowship.Cassandra Day / Hearst Connecticut MediaShow MoreShow Less

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.